ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Looking forward to 2023

<< Previous

Bullboard Posts

Next >>

Post by Gbathaton Dec 22, 2022 5:46pm

270 Views

Post# 35188196

Looking forward to 2023

Wishing all the longs a blessed and peaceful holiday season, and looking forward to a more prosperous 2023.

Thanks to those here who have shared due diligence. May your investments of time and treasure one day be rewarded.

Cheers.

<< Previous

Bullboard Posts

Next >>

Day trading vs. swing trading strategies for small-cap stocks